{"filing":{"accession_number":"0001819790-26-000046","cik":"0001819790","ticker":"TARS","company_name":"Tarsus Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-07-08","report_date":null,"primary_document":"tars-20260706.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000046/tars-20260706.htm"},"events":[{"id":16701,"run_id":14931,"accession_number":"0001819790-26-000046","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"Tarsus Pharmaceuticals completed its acquisition of iRenix Medical, Inc., a clinical-stage ophthalmic biopharmaceutical company, for approximately $75 million in upfront consideration ($37.5 million cash and 607,093 shares of stock) plus up to $490 million in milestone payments and revenue sharing. The transaction includes the acquisition of IRX-101, a late-stage asset that expands Tarsus's pipeline in eye care.","company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","filing_date":"2026-07-08","form":"8-K","submitted_at":null,"items":[{"id":14875,"accession_number":"0001819790-26-000046","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Tarsus Pharmaceuticals entered into an Agreement and Plan of Merger on July 6, 2026, acquiring iRenix Medical, Inc. for approximately $75 million in upfront consideration ($37.5 million cash and 607,093 shares of stock) plus up to $490 million in milestone payments and revenue sharing. This is a material acquisition of a clinical-stage biopharmaceutical company with a late-stage asset (IRX-101), clearly constituting M\u0026A activity under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T20:14:51.462679+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14876,"accession_number":"0001819790-26-000046","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Item 3.02 discloses an unregistered sale of Tarsus common stock as part of the iRenix acquisition consideration—$37.5 million in stock issued in a private placement exempt under Section 4(a)(2) and Regulation D. While the primary transaction is an M\u0026A activity (acquisition of iRenix Medical), Item 3.02 specifically focuses on the equity issuance component. The stock consideration is material and dilutive to existing shareholders, fitting the dilutive_issuance category, though the broader acquisition context (disclosed in Item 1.01 and the press release) is also significant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T20:14:51.462679+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14877,"accession_number":"0001819790-26-000046","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing announces the completion of Tarsus Pharmaceuticals' acquisition of iRenix Medical, Inc., a clinical-stage ophthalmic biopharmaceutical company. The transaction involves upfront consideration of approximately $75 million ($37.5 million cash and $37.5 million stock) plus potential milestone payments up to $490 million. This is a material acquisition of a late-stage asset (IRX-101) that expands Tarsus's pipeline and strategic positioning in eye care, clearly meeting the definition of M\u0026A activity under Item 1.01/2.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T20:14:51.462679+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14875,"accession_number":"0001819790-26-000046","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Tarsus Pharmaceuticals entered into an Agreement and Plan of Merger on July 6, 2026, acquiring iRenix Medical, Inc. for approximately $75 million in upfront consideration ($37.5 million cash and 607,093 shares of stock) plus up to $490 million in milestone payments and revenue sharing. This is a material acquisition of a clinical-stage biopharmaceutical company with a late-stage asset (IRX-101), clearly constituting M\u0026A activity under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T20:14:51.462679+00:00","company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","filing_date":"2026-07-08"},{"id":14876,"accession_number":"0001819790-26-000046","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Item 3.02 discloses an unregistered sale of Tarsus common stock as part of the iRenix acquisition consideration—$37.5 million in stock issued in a private placement exempt under Section 4(a)(2) and Regulation D. While the primary transaction is an M\u0026A activity (acquisition of iRenix Medical), Item 3.02 specifically focuses on the equity issuance component. The stock consideration is material and dilutive to existing shareholders, fitting the dilutive_issuance category, though the broader acquisition context (disclosed in Item 1.01 and the press release) is also significant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T20:14:51.462679+00:00","company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","filing_date":"2026-07-08"},{"id":14877,"accession_number":"0001819790-26-000046","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing announces the completion of Tarsus Pharmaceuticals' acquisition of iRenix Medical, Inc., a clinical-stage ophthalmic biopharmaceutical company. The transaction involves upfront consideration of approximately $75 million ($37.5 million cash and $37.5 million stock) plus potential milestone payments up to $490 million. This is a material acquisition of a late-stage asset (IRX-101) that expands Tarsus's pipeline and strategic positioning in eye care, clearly meeting the definition of M\u0026A activity under Item 1.01/2.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T20:14:51.462679+00:00","company_name":"Tarsus Pharmaceuticals, Inc.","ticker":"TARS","filing_date":"2026-07-08"}]}